Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab

Reversible Cardiotoxicity in a Young Patient Treated with Trastuzumab for Breast Cancer: A Case Report

“…An inhibitor of the conversion enzyme was prescribed and the dose of trastuzumab was reduced. Heart function progressively improved and trastuzumab was resumed without complications [8].…”

Cardiotoxicity in chemotherapeutic agents

“…Her preoperative clinical and imaging evaluations revealed normal cardio-circulatory parameters, with left ventricle ejection fraction (LVEF) of 76%. Well´known predisposing factors for occurrence of cardiac adverse effects of trastuzumab in this middle-aged woman were diabetes mellitus, arterial hypertension, and the antecedent chemotherapy schedule with anthracycline and cyclophosphamide [2]. At 7 cycles of trastuzumab, she developed heart failure (LVEF as low as 55%), and her heart function progressively improved after a 25% reduction in the chemotherapy dosage and use of the angiotensinconverting enzyme inhibitor.…”

“…A 54-year-old Brazilian female with breast cancer HER2positive in stage IIA (T2N0M0) underwent cycles of doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab after left mastectomy [2]. Her preoperative clinical and imaging evaluations revealed normal cardio-circulatory parameters, with left ventricle ejection fraction (LVEF) of 76%.…”

“…emphasized the acute (shortly after administration) and late (up to 12 years after the cycles) cardiotoxicity, and a rigorous evaluation of heart function should precede the beginning of chemotherapy and the cardiologic follow-up must be longstanding in all patients and with special attention to the elderly groups of people [2].…”